<DOC>
	<DOCNO>NCT00160043</DOCNO>
	<brief_summary>The purpose study determine whether study drug effective safe treatment patient non small cell lung cancer already receive one platinum base chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy Study New Chemotherapy Agent Treat Non Small Cell Lung Cancer .</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Non small cell lung cancer , Stage IIIB Stage IV One 1 prior platinumbased chemotherapy No uncontrolled concurrent illness Use highly effective birth control method male female reproductive potential Previous participation another trial within last 4 week Surgery within 10 day prior start study treatment Brain metastasis Confirmed diagnosis infection human immunodeficiency virus ( HIV ) Current treatment warfarin sodium ( Coumadin ) similar anticoagulation medication Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>